Pura Vida Investments’s Avadel Pharmaceuticals AVDL Stock Holding History

Pura Vida Investments’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-192,000	Closed	-$1.88M	–	239
2021 Q3	$1.88M	Sell	192,000 -3,200	-2%	-$25.2K	0.06%	192
2021 Q2	$1.31M	Buy	+195,200	New	+$1.55M	0.04%	172

Other funds holding AVDL

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Pura Vida Investments's AVDL Position: Q1 2023 in Review

Pura Vida Investments sold out of Avadel Pharmaceuticals (AVDL) in Q1 2023, closing a stake of 260,000 shares — an estimated $1.86M sold.

Pura Vida Investments first reported a position in AVDL in Q3 2019 and held it in 11 quarters. The position peaked at $4.55M in Q2 2020. 93 funds tracked by Wall St. Rank hold AVDL as of Q1 2023.

Pura Vida Investments reported no remaining Avadel Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Pura Vida Investments sold 260,000 Avadel Pharmaceuticals shares in Q1 2023, an estimated $1.86M.
Pura Vida Investments first reported a position in Avadel Pharmaceuticals in Q3 2019 and held it in 11 quarters.
Pura Vida Investments's Avadel Pharmaceuticals position peaked at $4.55M in Q2 2020.
93 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.